{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:50:12Z","timestamp":1791222612551,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA266704"],"award-info":[{"award-number":["R01 CA266704"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA228512"],"award-info":[{"award-number":["R01CA228512"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA163227"],"award-info":[{"award-number":["P01 CA163227"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA272390"],"award-info":[{"award-number":["P50 CA272390"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-19-1-0666"],"award-info":[{"award-number":["W81XWH-19-1-0666"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Docetaxel is the first-line chemotherapy for metastatic prostate cancer (PC), but clinically meaningful mechanisms of resistance remain to be established. Here we show, in an in vivo model of docetaxel resistant PC patient-derived xenografts, increased expression of genes that drive development of multiciliated cells including\n                    <jats:italic>FOXJ1<\/jats:italic>\n                    and its effectors, many of which regulate microtubules (MTs). Mechanistically, FOXJ1 overexpression confers docetaxel resistance in vitro and in vivo, which is associated with decreased docetaxel-mediated MT bundling. Overexpression of a MT-associated FOXJ1-regulated gene (\n                    <jats:italic>TPPP3<\/jats:italic>\n                    ) has similar effects. Conversely, FOXJ1 knockdown impairs basal MT function, enhances taxane binding to MTs, and increases docetaxel sensitivity. These results establish mechanistic causality between the FOXJ1 signaling axis, MT biology, and taxane resistance. Clinically,\n                    <jats:italic>FOXJ1<\/jats:italic>\n                    gene amplification is increased in taxane-treated PC patients. Moreover, in the CHAARTED clinical trial of docetaxel combined with androgen deprivation for metastatic PC, higher baseline FOXJ1 is predictive of decreased survival in PC patients treated with docetaxel, further supporting clinical relevance. Together, these findings identify a previously unrecognized clinically impactful mechanism of taxane resistance whose exploitation could stratify patients who will not benefit from taxane treatment.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-69556-0","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T08:33:42Z","timestamp":1771058022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["FOXJ1 mediates taxane resistance through regulation of microtubule dynamics"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6121-0875","authenticated-orcid":false,"given":"Fang","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4145-7117","authenticated-orcid":false,"given":"Ada","family":"Gjyrezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Fein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Labaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larysa","family":"Poluben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9410-3427","authenticated-orcid":false,"given":"Betul","family":"Ersoy-Fazlioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Dennehy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Voznesensky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniket","family":"Gad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9244-3807","authenticated-orcid":false,"given":"Eva","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Varkaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Einstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2399-1989","authenticated-orcid":false,"given":"Rupal S.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7378-262X","authenticated-orcid":false,"given":"Paraskevi","family":"Giannakakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4546-7371","authenticated-orcid":false,"given":"Steven P.","family":"Balk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"69556_CR1","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak, D. P. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513\u20131520 (2004).","journal-title":"N. Engl. J. Med"},{"key":"69556_CR2","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502\u20131512 (2004).","journal-title":"N. Engl. J. Med"},{"key":"69556_CR3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney, C. J. et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N. Engl. J. Med. 373, 737\u2013746 (2015).","journal-title":"N. Engl. J. Med"},{"key":"69556_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James, N. D. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387, 1163\u20131177 (2016).","journal-title":"Lancet"},{"key":"69556_CR5","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi, K. et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet 399, 1695\u20131707 (2022).","journal-title":"Lancet"},{"key":"69556_CR6","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith, M. R. et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N. Engl. J. Med 386, 1132\u20131142 (2022).","journal-title":"N. Engl. J. Med"},{"key":"69556_CR7","doi-asserted-by":"publisher","first-page":"T83","DOI":"10.1530\/ERC-17-0003","volume":"24","author":"J Shi","year":"2017","unstructured":"Shi, J. & Mitchison, T. J. Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic. Endocr. Relat. Cancer 24, T83\u2013T96 (2017).","journal-title":"Endocr. Relat. Cancer"},{"key":"69556_CR8","doi-asserted-by":"crossref","unstructured":"Maloney, S. M., Hoover, C. A., Morejon-Lasso, L. V. & Prosperi, J. R. Mechanisms of Taxane Resistance. Cancers (Basel) 12, 10.3390\/cancers12113323 (2020).","DOI":"10.3390\/cancers12113323"},{"key":"69556_CR9","doi-asserted-by":"publisher","first-page":"6019","DOI":"10.1158\/0008-5472.CAN-11-1417","volume":"71","author":"MS Darshan","year":"2011","unstructured":"Darshan, M. S. et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 71, 6019\u20136029 (2011).","journal-title":"Cancer Res"},{"key":"69556_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/35036335","volume":"2","author":"P Giannakakou","year":"2000","unstructured":"Giannakakou, P. et al. p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat. Cell Biol. 2, 709\u2013717 (2000).","journal-title":"Nat. Cell Biol."},{"key":"69556_CR11","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1158\/1078-0432.CCR-15-0269","volume":"21","author":"Y Zhu","year":"2015","unstructured":"Zhu, Y. et al. Antiandrogens inhibit abcb1 efflux and atpase activity and reverse docetaxel resistance in advanced prostate cancer. Clin. Cancer Res 21, 4133\u20134142 (2015).","journal-title":"Clin. Cancer Res"},{"key":"69556_CR12","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1158\/1535-7163.MCT-17-0179","volume":"16","author":"AP Lombard","year":"2017","unstructured":"Lombard, A. P. et al. ABCB1 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer. Mol. Cancer Ther. 16, 2257\u20132266 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"69556_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1158\/1535-7163.MCT-14-0155","volume":"14","author":"GE Duran","year":"2015","unstructured":"Duran, G. E. et al. Mechanisms of resistance to cabazitaxel. Mol. Cancer Ther. 14, 193\u2013201 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"69556_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/14728222.2017.1310841","volume":"21","author":"P Bugde","year":"2017","unstructured":"Bugde, P. et al. The therapeutic potential of targeting ABC transporters to combat multi-drug resistance. Expert Opin. Ther. Targets 21, 511\u2013530 (2017).","journal-title":"Expert Opin. Ther. Targets"},{"key":"69556_CR15","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41568-023-00612-3","volume":"23","author":"A Sajid","year":"2023","unstructured":"Sajid, A., Rahman, H. & Ambudkar, S. V. Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters. Nat. Rev. Cancer 23, 762\u2013779 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"69556_CR16","doi-asserted-by":"publisher","first-page":"6116","DOI":"10.1158\/1078-0432.CCR-06-0147","volume":"12","author":"T Yoshino","year":"2006","unstructured":"Yoshino, T. et al. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin. Cancer Res. 12, 6116\u20136124 (2006).","journal-title":"Clin. Cancer Res"},{"key":"69556_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-126","volume":"10","author":"AJ O\u2019Neill","year":"2011","unstructured":"O\u2019Neill, A. J. et al. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol. Cancer 10, 126 (2011).","journal-title":"Mol. Cancer"},{"key":"69556_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ccr.2012.07.016","volume":"22","author":"J Domingo-Domenech","year":"2012","unstructured":"Domingo-Domenech, J. et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell 22, 373\u2013388 (2012).","journal-title":"Cancer Cell"},{"key":"69556_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ccell.2014.11.013","volume":"27","author":"SJ Vidal","year":"2015","unstructured":"Vidal, S. J. et al. A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer. Cancer Cell 27, 223\u2013239 (2015).","journal-title":"Cancer Cell"},{"key":"69556_CR20","doi-asserted-by":"publisher","first-page":"7992","DOI":"10.1158\/0008-5472.CAN-10-0585","volume":"70","author":"ML Zhu","year":"2010","unstructured":"Zhu, M. L. et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 70, 7992\u20138002 (2010).","journal-title":"Cancer Res"},{"key":"69556_CR21","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1158\/0008-5472.CAN-13-2876","volume":"74","author":"M Thadani-Mulero","year":"2014","unstructured":"Thadani-Mulero, M. et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res. 74, 2270\u20132282 (2014).","journal-title":"Cancer Res"},{"key":"69556_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6548","volume":"5","author":"G Galletti","year":"2014","unstructured":"Galletti, G. et al. ERG induces taxane resistance in castration-resistant prostate cancer. Nat. Commun. 5, 5548 (2014).","journal-title":"Nat. Commun."},{"key":"69556_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fgene.2019.00023","volume":"10","author":"I Mukherjee","year":"2019","unstructured":"Mukherjee, I., Roy, S. & Chakrabarti, S. Identification of important effector proteins in the foxj1 transcriptional network associated with ciliogenesis and ciliary function. Front Genet 10, 23 (2019).","journal-title":"Front Genet"},{"key":"69556_CR24","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1242\/dev.074666","volume":"141","author":"SP Choksi","year":"2014","unstructured":"Choksi, S. P., Lauter, G., Swoboda, P. & Roy, S. Switching on cilia: transcriptional networks regulating ciliogenesis. Development 141, 1427\u20131441 (2014).","journal-title":"Development"},{"key":"69556_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.semcdb.2020.04.007","volume":"110","author":"M Lewis","year":"2021","unstructured":"Lewis, M. & Stracker, T. H. Transcriptional regulation of multiciliated cell differentiation. Semin Cell Dev. Biol. 110, 51\u201360 (2021).","journal-title":"Semin Cell Dev. Biol."},{"key":"69556_CR26","doi-asserted-by":"publisher","first-page":"942","DOI":"10.15252\/embj.201592821","volume":"35","author":"B Terre","year":"2016","unstructured":"Terre, B. et al. GEMC1 is a critical regulator of multiciliated cell differentiation. EMBO J. 35, 942\u2013960 (2016).","journal-title":"EMBO J."},{"key":"69556_CR27","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/ng.263","volume":"40","author":"X Yu","year":"2008","unstructured":"Yu, X., Ng, C. P., Habacher, H. & Roy, S. Foxj1 transcription factors are master regulators of the motile ciliogenic program. Nat. Genet 40, 1445\u20131453 (2008).","journal-title":"Nat. Genet"},{"key":"69556_CR28","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.bbrc.2004.09.207","volume":"324","author":"M Zhang","year":"2004","unstructured":"Zhang, M., Bolfing, M. F., Knowles, H. J., Karnes, H. & Hackett, B. P. Foxj1 regulates asymmetric gene expression during left-right axis patterning in mice. Biochem Biophys. Res Commun. 324, 1413\u20131420 (2004).","journal-title":"Biochem Biophys. Res Commun."},{"key":"69556_CR29","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl. Acad. Sci. USA 116, 11428\u201311436 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69556_CR30","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1172\/JCI132184","volume":"130","author":"A Gjyrezi","year":"2020","unstructured":"Gjyrezi, A. et al. Taxane resistance in prostate cancer is mediated by decreased drug-target engagement. J. Clin. Invest 130, 3287\u20133298 (2020).","journal-title":"J. Clin. Invest"},{"key":"69556_CR31","doi-asserted-by":"crossref","unstructured":"Eshun-Wilson, L. et al. Effects of alpha-tubulin acetylation on microtubule structure and stability. Proc. Natl. Acad. Sci. USA 116, 10366\u201310371 (2019).","DOI":"10.1073\/pnas.1900441116"},{"key":"69556_CR32","doi-asserted-by":"crossref","unstructured":"Carmona, B., Marinho, H. S., Matos, C. L., Nolasco, S. & Soares, H. Tubulin Post-Translational Modifications: The Elusive Roles of Acetylation. Biology (Basel) 12 (2023).","DOI":"10.3390\/biology12040561"},{"key":"69556_CR33","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nmeth.1493","volume":"7","author":"A Matov","year":"2010","unstructured":"Matov, A. et al. Analysis of microtubule dynamic instability using a plus-end growth marker. Nat. Methods 7, 761\u2013768 (2010).","journal-title":"Nat. Methods"},{"key":"69556_CR34","doi-asserted-by":"crossref","unstructured":"Thakkar, P. V. et al. CLIP-170S is a microtubule +TIP variant that confers resistance to taxanes by impairing drug-target engagement. Dev Cell, 10.1016\/j.devcel.2021.09.023 (2021).","DOI":"10.1016\/j.devcel.2021.09.023"},{"key":"69556_CR35","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.annonc.2021.06.003","volume":"32","author":"AA Hamid","year":"2021","unstructured":"Hamid, A. A. et al. Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial. Ann. Oncol. 32, 1157\u20131166 (2021).","journal-title":"Ann. Oncol."},{"key":"69556_CR36","doi-asserted-by":"crossref","unstructured":"Lopes, D., Seabra, A. L., Orr, B. & Maiato, H. alpha-Tubulin detyrosination links the suppression of MCAK activity with taxol cytotoxicity. J. Cell Biol. 222, 10.1083\/jcb.202205092 (2023).","DOI":"10.1083\/jcb.202205092"},{"key":"69556_CR37","doi-asserted-by":"crossref","unstructured":"Luo, J. et al. Tubulin acetyltransferases access and modify the microtubule luminal K40 residue through anchors in taxane-binding pockets. Nat. Struct. Mol. Biol. 10.1038\/s41594-024-01406-3 (2024).","DOI":"10.1038\/s41594-024-01406-3"},{"key":"69556_CR38","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1200\/JCO.2017.75.3335","volume":"36","author":"AK Morgans","year":"2018","unstructured":"Morgans, A. K. et al. Quality of life during treatment with chemohormonal therapy: analysis of e3805 chemohormonal androgen ablation randomized trial in prostate cancer. J. Clin. Oncol. 36, 1088\u20131095 (2018).","journal-title":"J. Clin. Oncol."},{"key":"69556_CR39","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/pros.23313","volume":"77","author":"HM Nguyen","year":"2017","unstructured":"Nguyen, H. M. et al. LuCaP prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease an\u2014d serve as models for evaluating cancer therapeutics. Prostate 77, 654\u2013671 (2017).","journal-title":"Prostate"},{"key":"69556_CR40","doi-asserted-by":"crossref","unstructured":"Galletti, G. et al. Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer. Clin. Cancer Res. 10.1158\/1078-0432.CCR-19-3018 (2020).","DOI":"10.1158\/1078-0432.CCR-19-3018"},{"key":"69556_CR41","doi-asserted-by":"publisher","first-page":"e92444","DOI":"10.1371\/journal.pone.0092444","volume":"9","author":"C Guzman","year":"2014","unstructured":"Guzman, C., Bagga, M., Kaur, A., Westermarck, J. & Abankwa, D. ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays. PLoS One 9, e92444 (2014).","journal-title":"PLoS One"},{"key":"69556_CR42","doi-asserted-by":"publisher","first-page":"8407","DOI":"10.1074\/jbc.M211163200","volume":"278","author":"JF Diaz","year":"2003","unstructured":"Diaz, J. F., Barasoain, I. & Andreu, J. M. Fast kinetics of Taxol binding to microtubules. Effects of solution variables and microtubule-associated proteins. J. Biol. Chem. 278, 8407\u20138419 (2003).","journal-title":"J. Biol. Chem."},{"key":"69556_CR43","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"69556_CR44","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"69556_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24\u201326 (2011).","journal-title":"Nat. Biotechnol."},{"key":"69556_CR46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","volume":"25","author":"R Arafeh","year":"2025","unstructured":"Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C. & Vazquez, F. The present and future of the Cancer Dependency Map. Nat. Rev. Cancer 25, 59\u201373 (2025).","journal-title":"Nat. Rev. Cancer"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69556-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69556-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69556-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T16:04:27Z","timestamp":1774454667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69556-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69556"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69556-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2763"}}